• Home
  • Sava Healthcare Ltd

Sava Healthcare Ltd

About Sava Healthcare Ltd

Sava Healthcare is a pharmaceutical company based in Pune, India. We are the CDMO of choice for leading global companies and provide a range of high-quality products to meet the needs of humans and animals. Our 15,000 sq. ft. Manufacturing Facility proudly holds accreditation from Health Canada, PIC/S and other global bodies. Our state-of-the-art R&D centre has developed over 325 formulations and secured multiple product and process patent. We specialise in dosage forms such as Tablets, Nasal Sprays, Oral powders for Suspension, Capsules, Ointments, Creams, and Gels.

Read more Show less
Certifications
  • GMP
    GMP
  • Other
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • IN
  • 2019
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Pharmaceutical company
Veterinary Company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024
View Exhibitor Profile

Sava Healthcare Ltd Resources (1)

  • News SAVA Healthcare to set up second manufacturing plant in Indore

    SAVA Healthcare conducted the ground-breaking ceremony of its second manufacturing plant, in the Smart Industrial Park (SIP) of Madhya Pradesh Industry Development Corporation (MPIDC) in March.

    SAVA Healthcare currently operates a Health Canada, PIC/s approved facility in Gujarat’s Surendranagar and an R&D centre in Pune.

    The proposed second plant will have a projected annual production capacity of 2,351.3 million SKUs which will include tablets, capsules, dry powder for oral suspension, ointments, nasal sprays, and dry powders for inhalation.

    Situated on 13.8 acres of prime land, the forthcoming facility will reportedly meet stringent regulatory standards such as EUGMP / USFDA of global pharma markets.
    15 Apr 2024